Popular Articles

CMS Proposes Payment Changes For Home Health Services To Protect Beneficiaries And Medicare
The Centers for Medicare & Medicaid Services (CMS) announced a proposed 2.2 percent home health market basket update to the home health prospective payment system (HH PPS) rates for calendar year (CY) 2010. Also, as part of ongoing efforts to address potential fraud and abuse with regards to outlier payments under the HH PPS, CMS is proposing modifications to its outlier policy.
generic viagra online
Loneliness Among Older People, Study
Professor Bo Malmberg and Professor Gerdt Sundstrç¶m at the School of Health Sciences in Jç¶nkç¶ping, Sweden have studied loneliness among older people.
News of the day
Sixteen States, DOJ Join Whistle-Blower Lawsuits Alleging Wyeth Defrauded Medicaid Programs
The U.S. Department of Justice and 16 states have joined two whistle-blower lawsuits filed in federal District Court in Massachusetts alleging that Wyeth defrauded the government by not offering the same discounts on two medications to Medicaid that it offered to hospitals, the Wall Street Journal reports. The lawsuits were initiated following a grand-jury investigation by the U.S. Attorney"s Office in Massachusetts (Johnson, Wall Street Journal, 5/19). The other states included in the lawsuits are California, Delaware, Florida, Illinois, Indiana, Louisiana, New York, Michigan, Nevada, New Hampshire, Tennessee, Texas, Virginia, Wisconsin and the District of Columbia (Barrett, AP/Austin American-Statesman, 5/18).According to the lawsuits, Wyeth from 2000 to 2006 sold hospitals a bundled package called the Protonix Performance Agreement, which included its acid-reflux drugs Protonix Oral and Protonix IV. The suits allege that Wyeth gave hospitals up to a 94% discount for the oral version under the deal, with the understanding that when patients were released from hospitals they would be switched from the intravenous version of the drug to the oral version. According to the complaint, Wyeth hoped to gain an edge in a competitive market for acid-reflux pills by taking advantage of its standing as the only company offering an IV acid-reflux drug. The Journal reports that Wyeth charged hospitals $20 per vial for the IV version of Protonix and $3 for the oral version.Medicaid rules stipulate that the program is entitled to the lowest price on prescription drugs, and drugmakers are required to pay states rebates if they offer discounts to any other entities. The lawsuits state that Wyeth avoided paying hundreds of millions of dollars to state Medicaid programs because it did not offer the programs the same discounts or provide rebates (Wall Street Journal, 5/19).The lawsuits are seeking financial penalties against Wyeth of up to three times the amount lost by Medicaid. Assistant Attorney General Tony West said, "By offering massive discounts to hospitals, but then hiding that information from the Medicaid program, we believe Wyeth caused Medicaid programs throughout the country to pay much more for these drugs than they should have." Wyeth spokesperson Doug Petkus said that Wyeth "believes that its pricing calculations were correct and intends to defend itself vigorously in these actions" (AP/Austin American-Statesman, 5/18).
Oncology

Cobalis Corporation Is Awarded Two New International Patents In Canada And Mexico For Its Revolutionary Anti-Allergy Relief Product PreHistin(R)

Cobalis Corporation (OTC:CLSC) was recently awarded two additional International Patents in Canada and Mexico and has a patent pending application in Japan. PreHistin® is patented, safe for long-term daily use and available without a prescription. It is available in a cherry flavored, all natural, proprietary cyanocobalamin (vitamin B12) sub-lingual lozenge that is taken twice daily to regulate allergy sufferers" response to both indoor and outdoor allergens with daily and year round usage. Cobalis representatives indicate, "Cyanocobalamin has an excellent safety record, has been safety accepted by the US FDA, and has no upper dosage limits or contra-drug indications. For over 50 years the FDA has approved cyanocobalamin as a drug for anemia. Each PreHistin® lozenge contains 3.3mg Cyanocobalamin. For less than $1.00 per day, twice daily use of PreHistin® has been clinically shown to significantly increase serum vitamin B12 levels, making PreHistin® a cost effective and convenient alternative to other Vitamin B12 therapies, including needle injections." Cobalis Board Member, Dr. Kevin Prendiville states, "These new patents, in addition to the European Union, Australian and two U.S. patents further strengthen the value and assets of Cobalis Corporation intellectual properties. Furthermore, PreHistin®"s box, labeling and related box insert have been approved by DSHEA (Dietary Supplement Health and Education Act) regulation attorneys." About Cobalis Corp-Prehistin® "The World"s First Pre-Histamine" Headquartered in Irvine, California, Cobalis Corp. is an over the counter pharmaceutical and nutraceutical company. Its flagship product, PreHistin® is designed to prevent the primary causes of airborne allergies. PreHistin®, "The World"s First Pre-Histamine" is the only Phase III clinically tested sublingual product fully patented for long term and daily use without a prescription to help relieve allergy sufferers of both indoor and outdoor allergens. PreHistin® is manufactured by Monarch Nutraceutical Inc., a division of Nutraceutical Corporation in Ogden Utah. Nutraceutical Corp. (NUTR) was the original manufacturer of PreHistin® under the name Alleratin, which was distributed to thousands of allergy suffers without cost for compassionate use. Additional PreHistin® manufacturing partners include Marrs Printing, Walnut, CA and Merical Inc, Anaheim, CA. Domestic and international PreHistin® orders are currently fulfilled by International Sales and Marketing (ISM), Newark, NJ. For product information and ordering please visit at http://www.PreHistin.comor call toll free 1-877-4POLLEN. For additional company information please visit their website at http://www.Cobalis.com Cobalis Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):